Cited by 342Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

The FDA's Assessment of Two Drugs for Chronic Weight Management

Colman, Eric, Golden, Julie, Roberts, Mary, Egan, Amy, Weaver, Joyce, Rosebraugh, Curtis·2012·New England Journal of Medicine

DOI 10.1056/nejmp1211277

Open this paper in CoChat — free account

Abstract

After weighing the risks and benefits, the FDA recently approved two new drugs as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related coexisting condition.

Integrity signals

Registry

Crossref · 10.1056/nejmp1211277

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP)
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 565
Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study
O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 525
The Obesity Epidemic and Its Impact on Hypertension
Nguyen, T., & Lau, D. C. W. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.01.001 · Cited by 223
Use of topiramate in pregnancy and risk of oral clefts
Margulis, A. V., Mitchell, A. A., Gilboa, S. M., Werler, M. M., Mittleman, M. A., Glynn, R. J., & Hernández–Dı́az, S. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.07.008 · Cited by 178
Serotonergic drugs and valvular heart disease
Rothman, R. B., & Baumann, M. H. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902931524 · Cited by 144
Obesity and type 2 diabetes: which patients are at risk?
Garber, A. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01536.x · Cited by 114

Show all 13 references

Sorted by citations

Items 101–200 of 341

Delineating a serotonin 1B receptor circuit for appetite suppression in mice
Li, L., Wyler, S. C., Mercado, L. L., Xu, B., Oh, Y., SWATI, S., Chen, X., Wan, R., Arnold, A. G., Jia, L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212307 · Cited by 13
Fixed-dose combination of phentermine–topiramate for the treatment of obesity
Halpern, B., Faria, A. M., & Halpern, A. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.13 · Cited by 13
Comparison of brain serotonin transporter using [I-123]-ADAM between obese and non-obese young adults without an eating disorder
Wu, C., Chang, C.-S., Yang, Y. K., Shen, L.-H., & Yao, W.-J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170886 · Cited by 13
Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard
Giovanni, C. B. S., Sweeney, B. R., Skelton, J. A., Kelsey, M. M., & Kelly, A. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab276 · Cited by 13
Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?
Engeli, S., & Jordan, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0374-z · Cited by 12
The Protective Effects of Danggui-Baizhu-Tang on High-Fat Diet-Induced Obesity in Mice by Activating Thermogenesis
Zhao, L., Zhu, X., Cong, R., Yang, X., & Zhu, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01019 · Cited by 12
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 13
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
Harrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 11
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3-L1 preadipocytes via AKT/mTOR pathway
Yoon, J.-S., Kim, S., Ha, J., Kang, I., & Choe, W. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5209 · Cited by 9
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine–Topiramate to Prevent Exposure During Pregnancy
Sarayani, A., Donahoo, W. T., Hampp, C., Brown, J. D., & Winterstein, A. G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1743 · Cited by 11
Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice
Carmody, J. S., Ahmad, N. N., Machineni, S., Lajoie, S., & Kaplan, L. M. (2015) · Endocrinology · doi:10.1210/en.2015-1226 · Cited by 11
Topiramate-Associated Weight Loss in a Veteran Population
Kazerooni, R., & Lim, J. (2016) · Military Medicine · doi:10.7205/milmed-d-14-00636 · Cited by 11
Obesity in Europe – does anybody care?
Astrup, A. V., Rössner, S., Finer, N., & Gaal, L. V. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.783016 · Cited by 12
Pharmacotherapy for weight loss
Rueda‐Clausen, C. F., & Padwal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3526 · Cited by 10
Obesity consults—comprehensive obesity management in 2013: Understanding the shifting paradigm
Kushner, R. F., Apovian, C. M., & Fujioka, K. (2013) · Obesity · doi:10.1002/oby.20627 · Cited by 9
Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates
Sasaki, T., Shimpuku, M., Kitazumi, T., Hiraga, H., Nakagawa, Y., Shibata, H., Okamatsu‐Ogura, Y., Kikuchi, O., Kim, H., Fujita, Y., et al. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0333 · Cited by 9
The toxicological assessment of two anti-obesity drugs in C. elegans
Aitlhadj, L., & Stürzenbaum, S. R. (2013) · Toxicology Research · doi:10.1039/c2tx20096a · Cited by 9
Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People
Tsigos, C., Bitzur, R., Kleinman, Y., Cohen, H., Cahn, A., Brambilla, G., Mancia, G., & Grassi, G. M. (2013) · Diabetes Care · doi:10.2337/dcs13-2021 · Cited by 8
Potential anti-obesity effects of a long-acting cocaine hydrolase
Zheng, X., Deng, J. T., Zhang, T., Yao, J., Zheng, F., & Zhan, C. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.05.010 · Cited by 8
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10410-0 · Cited by 6
Therapies for Obesity and Medication-Associated Weight Gain
Howland, R. H. (2013) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20130411-01 · Cited by 6
Obesity and trends in malpractice claims for physicians and surgeons
Weber, C. E., Talbot, L. J., Geller, J. M., Kuo, M. C., Wai, P. Y., & Kuo, P. C. (2013) · Surgery · doi:10.1016/j.surg.2013.04.026 · Cited by 6
Obesity, Adipose Tissue, Inflammation and Update on Obesity Management
Cordido, F. (2014) · Obesity & Control Therapies Open Access · doi:10.15226/2374-8354/1/2/00110 · Cited by 7
Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Dental considerations for patients taking weight-loss medications
Donaldson, M., Goodchild, J. H., & Ziegler, J. (2014) · The Journal of the American Dental Association · doi:10.14219/jada.2013.3 · Cited by 5
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
Jing, M., Wang, S., Li, D., Wang, Z., Li, Z., Lu, Y., Sun, T., Qiu, C., Chen, F., Yu, H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.761966 · Cited by 5
Fluoxetine for adult overweight or obese people
Meléndez, G., Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Galicia, C. S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011688 · Cited by 5
The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes
Hollander, P. A. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.101 · Cited by 5
New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy
Catoira, N. P., Viale, L., Girolamo, G. D., & González, C. D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.884494 · Cited by 5
Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity
Gorain, B., Choudhury, H., Sengupta, P., Verma, R. K., & Pandey, M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_10 · Cited by 4
Relación del consumo de productos para bajar de peso con el sobrepeso y la obesidad en profesores universitarios de Puebla, México
Ceja-Ramírez, L. G. (2015) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v63n1.48131 · Cited by 4
Obesity & the First Law of Thermodynamics
Walsh, J. A. (2013) · The American Biology Teacher · doi:10.1525/abt.2013.75.6.10 · Cited by 4
Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3
Obesity Hypertension: Clinical Aspects
Batisky, D. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-31107-4_17 · Cited by 3
Unambiguous Identification of Obesity Trials
Zarin, D. A., & Tse, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215018 · Cited by 3
Structure Based Virtual Screening and Molecular Docking Studies for Identification of Allosteric Inhibitors against Zika Virus Protease NS2B-NS3
Fatima, M., Khan, M. S., Rashid, H., Mehmood, A., Kanwal, S., Rasheed, M. A., & Jamil, F. (2018) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/2018.50.5.1709.1715 · Cited by 3
Childhood Obesity and Blood Pressure Regulation
Batisky, D. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-490-6_17 · Cited by 2
The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation
Chawla, A., Carls, G. S., Deng, E., & Tuttle, E. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0300-0 · Cited by 2
Review of Current Anti-Obesity Drugs in Obese Adults
Nozari, N., Pourshams, A., & Mokhtare, M. (2015) · GOVARESH · Cited by 2
Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update
Lee, E. J., & Kim, T. N. (2016) · The Korean Journal of Obesity · doi:10.7570/kjo.2016.25.3.121 · Cited by 2
Neuroendocrine Control of Energy Stores
Cone, R. D., & Elmquist, J. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00035-6 · Cited by 2
Innovating and expanding weight loss strategies for breast cancer survivors
Sheng, J. Y.-S., & Stearns, V. (2021) · Oncotarget · doi:10.18632/oncotarget.27898 · Cited by 2
Therapeutic potential of natural compounds in the treatment of obesity: A review on computational and experimental studies
Athista, M., Harsiddhi, A., Nachiyar, C. V., & Sunkar, S. (2023) · Medicinal Plants - International Journal of Phytomedicines and Related Industries · doi:10.5958/0975-6892.2023.00008.4 · Cited by 2
Prescription Drugs and Dietary Supplements for Weight Loss
Smith, R. E. (2015) · Advances in Obesity Weight Management & Control · doi:10.15406/aowmc.2015.03.00045 · Cited by 4
Clinical Trials for Adolescent Obesity
Schwimmer, J. B. (2013) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2013.1661 · Cited by 2
Cariprazine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
Smartphone-assisted colorimetric detection of fluoxetine with phyto-capped silver nanoparticles: selectivity and molecular mechanisms
Thepchuay, Y., Khunthongchan, K., Phonchai, A., Nacapricha, D., Zahn, D., & Wonglakhon, T. (2026) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-026-02458-w · Cited by 1
Lorcaserin: Making headway
Gershome, C. (2015) · Diabesity · doi:10.15562/diabesity.2015.9
Anti-Obesity Agents and the US Food and Drug Administration
Casey, M. F., & Mechanick, J. I. (2014) · Current Obesity Reports · doi:10.1007/s13679-014-0115-x · Cited by 2
Obesity Hypertension: Clinical Aspects
Batisky, D. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-31420-4_17-1 · Cited by 1
Aproximaciones farmacológicas para el tratamiento de la obesidad
Londoño-Lemos, M. E. (2017) · Revista Colombiana de Ciencias Químico Farmacéuticas · doi:10.15446/rcciquifa.v46n1.67293 · Cited by 1
Nanotechnology in the Context of Obesity
Natarajan, S. B., Chandran, S. P., & Kutty, M. K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6408-0_11 · Cited by 1
Medications Indicated for Chronic Weight Management
Ryan, D. H., & Yockey, S. R. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_31 · Cited by 1
Methylphenidate (D,L)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Brexpiprazole
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Clozapine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Brexanolone
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
Milnacipran
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Esketamine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Flurazepam
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Lithium
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
Ruokahalun säätely ja lihavuuden lääkehoito : lihavuuslääkkeiden tehoseulontamenetelmä seeprakalalla
Heine, S. (2014) · Työväentutkimus Vuosikirja
Predictors of Successful Weight Loss Following Bariatric Surgery.
Broder, F. R., Cahn, S. C., DiTomasso, R. A., Petrucci, R., & Geno, P. S. (2012) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Pharmakologische Ansätze in der Adipositastherapie
Lechleitner, M. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Lorcaserin: a guide to its use in chronic weight management
Lyseng-Williamson, K. A., & Hoy, S. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0056-6
An Approach to Obesity as a Cardiometabolic Disease: Potential Implications for Clinical Practice
(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608059140114020003
The Doctor’s Tool Kit: Pharmacotherapy for the Patient with Obesity
Bray, G. A., & Ryan, D. H. (2015) · Endocrine updates · doi:10.1007/978-1-4939-2146-1_6
Care of the Obese Patient
Gardner, B., & Pervez, F. (2015) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_60-1
Control of Appetite/Satiety and Energy Balance
Elmquist, J. K., & Horton, J. D. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch28
Relación del consumo de productos para bajar de peso con el sobrepeso y la obesidad en profesores universitarios de Puebla, México The relation between overweight and obesity with the use of weight loss products in university professors of Puebla, Mexico
Original, I., Ceja-Ramírez, L. G., Rivadeneyra‐Espínoza, L., & Soto-Vega, E. N. (2015)
Functional characterization of Phosphodiesterase-4A in behavior and obesity
Hansen, R. (2014) · doi:10.33915/etd.583
Das pharmakologische Management von Adipositas
Toplak, H. (2016) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Obesity and Trends in Malpractice Claims for Physicians and Surgeons
Talbot, L. J., Weber, C., Kuo, M. C., Li, N. Y., & Kuo, P. C. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2012.10.082
Nuevas drogas en el tratamiento de la Obesidad y el Sobrepeso New drugs for the treatment of obesity and overweight
Politi, M. T., & Isolabella, D. (2013)
Treating an obese infertile patient – Is there an algorithm for success?
Allahbadia, G. (2016) · IVF Lite · doi:10.4103/2348-2907.204666
Weight Loss Medication in Bariatric Surgery
Lee, S. E. (2017) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2017.6.1.1
ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA
Tamargo, J. L. (2016)
Medications Indicated for Chronic Weight Management
Ryan, D. H., & Yockey, S. R. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_31-1
Gastric bypass : positive and negative health effects
Backman, O. (2017) · Figshare
Bioresponsive Drug Delivery by Microneedle Patches.
Zhang, Y. (2018) · NCSU Libraries Repository (North Carolina State University Libraries)
Public access to data at drug agencies
Gøtzsche, P. C. (2019) · CRC Press eBooks · doi:10.1201/9780429084034-11
Влияние гибискуса и оральных препаратов на уровень глюкозы в крови
Исматова, М. Ш., Юлдашева, Ф. З., & Алимова, О. (2021) · Общество и инновации · doi:10.47689/2181-1415-vol2-iss8/s-pp333-338
Amphetamine (D,L)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
Faculty Opinions recommendation of Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis.
Heisler, L. K., & D’Agostino, G. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718163291.793490349
Galantamine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Flunitrazepam
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Amoxapine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Escitalopram
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 1
Amphetamine (D)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Oxazepam
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Methylphenidate (D)
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Loflazepate
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Naltrexone/Bupropion
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Clomipramine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Chlorpromazine
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Clonazepam
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029

Authors: Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C.
Affiliations: United States Food and Drug Administration (US)
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-10-25
Volume: 367
Issue: 17
Pages: 1577-1579
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp1211277
OpenAlex: W2331430051
Cited by: 342
References: 13
Citations by year: 2026: 4 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 14 · 2020: 162 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 22 · 2014: 24 · 2013: 42 · 2012: 3
FWCI: 21.58
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords: chronic weight management, obesity, overweight adults, FDA drug approval, anti-obesity drugs, adjunctive therapy, hypocaloric diet, physical activity, comorbidities, risk-benefit assessment
MeSH terms: Abnormalities, Drug-Induced, Topiramate, Benzazepines, Delayed-Action Preparations, Drug Combinations, Female, Fructose, Humans, Obesity, Phentermine, Pregnancy, United States, United States Food and Drug Administration, Weight Loss, Drug Approval, Serotonin Receptor Agonists, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The FDA's Assessment of Two Drugs for Chronic Weight Management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks